SMED Clinical Research joins the Barcelona & Madrid Health Hub
Joining Barcelona & Madrid Health Hub marks an important step for SMED Clinical Research as the company continues to strengthen its presence within the healthcare and life sciences ecosystem. It creates new opportunities to stay close to innovation, collaborate with leading organisations, and better understand the evolving needs of sponsors, clinical sites and the patients they serve.
Why Does Clinical Evidence Matter?
Innovation in health only creates value when it reaches patients. Behind every approved therapy, diagnostic or digital health solution there is a long chain of scientific and regulatory decisions that must all be right: a well-designed protocol, feasible and well-selected sites, reliable data, rigorous statistics and full regulatory compliance.
When one of those links is weak, the consequences are serious. Studies are delayed or fail to recruit, data are questioned, promising assets lose years of development and investment is wasted. In the most critical cases, patients are exposed to unnecessary risk, and products that could have helped them never reach the market.
These risks are greatest in the areas where science moves fastest: oncology, immunology, advanced therapies and AI-driven innovation. In these fields, the difference between success and failure is usually decided long before the first patient is enrolled.
How Can SMED Clinical Research Help?
SMED Clinical Research is a full-service CRO and medical advisory company founded in February 2024 by Dr. Sonia Maciá, MD, PhD, MBA, a medical oncologist with more than 20 years of experience in clinical research. Our philosophy is simple: we are not just advisors, we are partners. We turn impossible into possible.
We combine clinical development with real-world clinical practice, and we work hand in hand with sponsors and clinical sites to deliver efficient, high-quality trials. We apply critical thinking and advanced machine-learning-driven biomarker and genomic signatures to optimise drug modelling and maximise the probability of success in developing innovative therapies.
What we offer:
- Strategic medical advisory — protocol development, pathway planning with regulatory considerations, customised site recommendations with patient-estimation metrics and feasibility assessment integrated with clinical practice.
- Clinical operations and regulatory — operational strategy, start-up, oversight and full regulatory support, tailored to each programme.
- Medical monitoring and medical support — data analysis and interpretation, medical data review, safety oversight, and leadership of Data Safety Monitoring Board meetings, investigator meetings and advisory boards.
- Medical writing — protocols, clinical study reports, patient informed consent forms, manuscripts and all protocol-related documents for regulatory submissions.
- Biostatistics and data management — study design and statistical analysis, including adaptive and Bayesian designs, sample-size calculation and analysis of censored data.
- Data science and AI — biomarker and genomic signature development, explainable machine learning models and in silico drug design.
- Financial and market analysis — medical-perspective reports tailored by indication or study status, combined with market analysis and financial modelling for investors.
Therapeutic and functional expertise:
- Oncology — extensive experience across all solid tumours
- Immuno-oncology, cancer immunotherapy and advanced therapies (ATMPs)
- Medical devices
- Neurology, endocrinology, internal medicine, rheumatology and haematology
- Clinical development, data management, biostatistics, regulatory and strategic advice, site selection and medical monitoring
Where we work:
- All phases, from first-in-human Phase I studies to registration and post-authorisation
- Global reach across Europe, Israel, USA, APAC and Latin America
- Sponsor-side and site-side perspective
Proven Experience in Clinical Development
Our team has been involved in pivotal trials that ended in FDA approval, and has supported sponsors at every stage of the clinical development continuum.
SMED Clinical Research is registered as an SME with the European Medicines Agency (EMA) and takes part in the ACTEU (Accelerating Clinical Trials in the EU) initiative, and is a member of AseBio, the Spanish Bioindustry Association.
Our data science team develops models designed to be defensible rather than black boxes. The MET-score, an explainable machine learning model that continuously estimates metastatic risk in prostate cancer from transcriptomic data, was presented at ASCO and at the GUARD Consortium. We have also designed a new anti-DLL3 therapeutic candidate entirely in silico, without a single wet-lab experiment, for small cell lung cancer and other neuroendocrine tumours.
Our medical and operational teams have also represented our partners at ASCO, ESMO, ESMO MAP, ASCO GU, NextGen Biomed London and the Clinical Research Innovation Forum.
Through SMED Academy we train clinical research professionals, with modules on clinical operations, clinical research and regulatory affairs, and dedicated programmes on ATMPs, immuno-oncology and medical devices.
Accelerating Innovation:
From first-in-human studies to registration, and from biomarker signatures to regulatory submissions, clinical development should never be left to chance. A proactive, science-driven strategy helps protect patients, de-risk investment and bring better solutions to the people who need them.
We are delighted to become part of Barcelona & Madrid Health Hub and to contribute our clinical research expertise to its ecosystem of digital health innovators, healthcare organisations and investors.
For any enquiries, please feel free to contact us:
info@smedcr.com · +34 606 432 153 · www.smedcr.com